Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MBRC-101 by MBrace Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
MBRC-101 is under clinical development by MBrace Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
MBRC-101 by MBrace Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
MBRC-101 is under clinical development by MBrace Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
MBRC-101 by MBrace Therapeutics for Solid Tumor: Likelihood of Approval
MBRC-101 is under clinical development by MBrace Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
MBRC-101 by MBrace Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
MBRC-101 is under clinical development by MBrace Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...